Yayın:
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis

Basit Görünüm
dc.contributor.authorYalçın, Şuayib
dc.contributor.buuauthorOrhan, Bülent
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Onkoloji Ana Bilim Dalı
dc.contributor.scopusid6701877552
dc.contributor.scopusid7101652066
dc.date.accessioned2021-11-12T10:12:12Z
dc.date.available2021-11-12T10:12:12Z
dc.date.issued1999-09-15
dc.identifier.citationOrhan, B. ve Yalçın, Ş. (1999). "What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis". Cancer, 86(6), 1095-1096.
dc.identifier.doi10.1002/(SICI)1097-0142(19990915)86:6<1095::AID-CNCR28>3.0.CO;2-K
dc.identifier.endpage1096
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.issue6
dc.identifier.pubmed10491539
dc.identifier.scopus2-s2.0-0033568682
dc.identifier.startpage1095
dc.identifier.urihttps://doi.org/10.1002/(SICI)1097-0142(19990915)86:6<1095::AID-CNCR28>3.0.CO;2-K
dc.identifier.urihttps://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/(SICI)1097-0142(19990915)86:6%3C1095::AID-CNCR28%3E3.0.CO;2-K
dc.identifier.urihttp://hdl.handle.net/11452/22633
dc.identifier.volume86
dc.identifier.wos000082582900028
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationYurt içi
dc.relation.journalCancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOncology
dc.subjectRecombinant-human-erythropoietin
dc.subjectChronic anemia
dc.subjectChemotherapy
dc.subjectNeurons
dc.subject.emtreeCisplatin
dc.subject.emtreeCytotoxic agent
dc.subject.emtreeRecombinant erythropoietin
dc.subject.emtreeAnemia
dc.subject.emtreeCancer
dc.subject.emtreeCancer patient
dc.subject.emtreeCost benefit analysis
dc.subject.emtreeDrug cost
dc.subject.emtreeHuman
dc.subject.emtreeHypertension
dc.subject.emtreeLetter
dc.subject.emtreePriority journal
dc.subject.emtreeProphylaxis
dc.subject.emtreeThrombosis
dc.subject.scopusPeripheral Nervous System Diseases; Oxaliplatin; Goshajinkigan
dc.subject.wosOncology
dc.titleWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis
dc.typeLetter
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbi Onkoloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Orhan_ve_Yalçın_1999.pdf
Boyut:
33.02 KB
Format:
Adobe Portable Document Format
Açıklama
İndir

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications